Advertisement

Topics

DOR BioPharma, Inc. Company Profile

17:25 EST 21st January 2019 | BioPortfolio

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.


News Articles [1279 Associated News Articles listed on BioPortfolio]

Hillstream BioPharma looks forward to pre-IND discussion with FDA in Q4

Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Hillsteam BioPharma is developing targeted cancer therapeutic...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vacc...

Vitro Diagnostics/DBA Vitro Biopharma: Vitro Biopharma Receives ISO 9001 Certification

GOLDEN, CO / ACCESSWIRE / December 11, 2018 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma ('Vitro') one of the world's emerging biotechnology companies focused on Umbilical Cord Mes...

This Day That Year: Cue Biopharma

Shares of Cue Biopharma Inc. (CUE) are down nearly 74% from their 52-week high of $17.99 recorded on March 14, 2018.

#jobs #lifescience BioPharm/BioTech

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: BioPharm/BioTech .MA-Cambridge, BioPharma/BioTech BIOPHARMA/BIOTECH Amgen, In...

How the US-Mexico trade deal could impact the biologics market

BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lioneâs biopharma practice group, the provisional detail revealed from the US administrationâs proposed trade d...

Biopharma Market: An Inside Look

Survey results reveal how slow-motion trends are driving biopharma growth

MedCity News launches biopharma-focused newsletter

The biotech century has arrived, and it’s consequently now more important than ever for us to highlight our coverage of

Drugs and Medications [9 Associated Drugs and Medications listed on BioPortfolio]

Alferon [Hemispherx Biopharma, Inc]

NA

Yupelri [The Ritedose Corporation]

Yupelri (Revefenacin) Inhalation Solution 175 mcg/3 mL

Keveyis [Strongbridge US Inc.]

These highlights do not include all the information needed to use KEVEYIS safely and effectively. See full prescribing information for KEVEYIS. KEVEYIS (dichlorphenamide) tablets, for oral use Initial...

Macrilen [Strongbridge U.S. Inc]

These highlights do not include all the information needed to use MACRILEN safely and effectively. See full prescribing information for MACRILEN.MACRILEN (macimorelin) for oral solution Initial U.S. A...

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation.

At the turn of the century, the pharmaceutical industry began a transition toward a focus on oncology, rare diseases, and other areas of high unmet need that required a new, more complex approach to d...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeut...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [148 Associated Companies listed on BioPortfolio]

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "DOR BioPharma, Inc." on BioPortfolio

We have published hundreds of DOR BioPharma, Inc. news stories on BioPortfolio along with dozens of DOR BioPharma, Inc. Clinical Trials and PubMed Articles about DOR BioPharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DOR BioPharma, Inc. Companies in our database. You can also find out about relevant DOR BioPharma, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record